Radiation-Associated Sarcoma in a Resource-Constrained Setting: A Decade of Real-World Outcomes From a Tertiary Care Sarcoma Center in India This study illustrates a pragmatic model for implementing ...
CLD-201, an allogeneic adipose stem-cell loaded oncolytic virus, received FDA fast track designation for soft tissue sarcoma treatment. Fast track designation expedites drug development and review for ...
University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate ...
LP-284 targets DNA repair defects in cancers, showing promise in preclinical and early clinical trials across multiple cancer types. The FDA's orphan drug designation supports LP-284's development for ...
The global, regional, and national burden of soft tissue sarcomas and other extraosseous sarcomas, 1990-2021: A systematic analysis for the Global Burden of Disease study 2021. This is an ASCO Meeting ...
A cohort of 253 isolated LR resections from 3211 primary STS resections enabled evaluation of post-recurrence prognosticators with median 5.3-year follow-up and 83 disease-specific deaths. Higher LR ...
The National Comprehensive Cancer Network (NCCN) published new guidelines for pediatric soft tissue sarcoma (STS), growing the NCCN’s library of guidelines to now cover 91 topics in cancer care. 1 ...
The National Comprehensive Cancer Network ® (NCCN ®) today published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Pediatric Soft Tissue Sarcomas. This is the 7th NCCN ...
Soft tissue sarcoma (STS) is a rare type of cancer that can quietly grow in the connective tissues of the body—such as fat, muscles, nerves, blood vessels, or beneath the skin. Although it represents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results